Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Multidrug resistance protein MexY (MexY) is a critical inner membrane transporter component of the MexXY-OprM efflux system in Pseudomonas aeruginosa, belonging to the Resistance-Nodulation-Division (RND) family (UniProt: P52478). It is primarily responsible for the efflux of a wide range of antibiotics, most notably aminoglycosides, but also tetracyclines, macrolides, and some fluoroquinolones (Westbrock-Wadman et al., 1999, PubMed: 10516754). MexY works as part of a tripartite complex where it captures substrates and, with the help of the adapter protein MexX, delivers them to the outer membrane porin OprM for extrusion into the extracellular space. The expression of the mexY gene is typically regulated by the repressor MexZ; however, mutations in mexZ or other regulatory pathways often lead to the constitutive overexpression of MexY, resulting in high-level multidrug resistance (Llanes et al., 2011, PubMed: 25645828). This resistance mechanism is a major clinical challenge in treating chronic Pseudomonas infections, particularly in patients with cystic fibrosis. Consequently, MexY is a significant target for the development of efflux pump inhibitors (EPIs) designed to restore antibiotic susceptibility in resistant strains. Research into MexY inhibitors aims to enhance the efficacy of existing antimicrobial therapies by blocking the primary escape route for these drugs.
MexY acts as the substrate-recognition and energy-coupling component of the MexXY-OprM efflux pump. It utilizes the proton motive force to drive the active transport of antibiotics from the periplasm or cytoplasm through the MexX adapter to the OprM exit duct (Morita et al., 2001, PubMed: 11133754).
7 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Multidrug resistance protein MexY (MexY) (MexY).